세계의 항체 생산 시장 규모, 점유율, 동향 분석 : 제품별, 종류별, 프로세스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Antibody Production Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables, Software), By Type (Polyclonal Antibody, Monoclonal Antibody), By Process, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,836,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,322,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,292,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

항체 생산 : 시장 개요

세계의 항체 생산 시장 규모는 2024년에 154억 4,000만 달러로 평가되었으며, 2033년에는 398억 달러에 달하고, 2025년부터 2033년까지 CAGR은 11.2%로 성장할 것으로 예측됩니다.

암, 당뇨병, 심혈관질환 등 만성질환의 유병률 증가와 치료용 항체에 대한 수요 증가로 항체 생산 시장이 급성장하고 있습니다.

개인화 항체와 차세대 항체

전 세계 항체 생산 시장은 기존의 단클론항체에서 보다 복잡한 차세대 항체 생산으로 전환하면서 큰 변화를 겪고 있습니다. 이중특이성항체, 항체약물접합체(ADC), 인공 단클론항체 등이 보다 높은 정확도와 효과로 질병을 표적화하는 중요한 도구로 부상하고 있으며, 맞춤형 치료는 점점 더 표준치료가 되어가고 있습니다. 이러한 새로운 치료법은 치료 성과를 향상시킬 뿐만 아니라, 바이오 제약사들에게 치열한 경쟁 속에서 포트폴리오를 차별화할 수 있는 새로운 기회를 열어줄 수 있습니다.

차세대 항체의 등장은 고도의 전문화된 생산 기술에 대한 수요를 촉진하고 있습니다. 비교적 표준화된 생산 공정에 의존하는 기존 mAb와 달리 이중특이성항체 및 ADC는 보다 정교한 세포주 개발, 정제 기술, 접합 플랫폼이 필요합니다. 제조업체들은 이러한 진화하는 요구에 부응하기 위해 고밀도 관류 바이오리액터, 모듈식 일회용 시스템, 통합형 연속 바이오프로세스 등 혁신적인 솔루션을 빠르게 채택하고 있습니다. 이러한 기술적 진보는 복잡한 생물학적 제제에 요구되는 높은 품질과 안전 기준을 유지하면서 비용 효율적인 확장성을 달성하는 데 필수적입니다.

차세대 항체 파이프라인을 활용하고자 하는 기존 제약사 및 신생 바이오기업들의 강력한 투자 흐름에 힘입어 시장 성장이 더욱 강화되고 있습니다. 파트너십, 인수, 생산능력 확대 노력은 전 세계적으로 가속화되고 있으며, 특히 바이오제약 인프라에 많은 투자를 하고 있는 지역에 중점을 두고 있습니다. 규제 프레임워크가 이러한 혁신적인 치료법에 대응할 수 있도록 진화하고 있는 가운데, 맞춤형 항체 및 차세대 항체 관련 수요에 대응할 수 있는 생산능력을 갖춘 기업은 확대되는 시장에서 더 큰 시장 점유율을 확보할 수 있는 유리한 위치에 있습니다. 결국, 과학적 혁신, 뛰어난 제조 기술, 전략적 투자의 융합이 항체 생산의 전망을 재구성하고 강력한 장기적 성장을 지속하고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 항체 생산 시장 : 변동 요인과 경향

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인의 영향 분석
  • 시장 성장 억제요인의 영향 분석
• 업계 분석 툴
  • PESTEL 분석
  • Porter's Five Forces 분석

제4장 항체 생산 시장 : 제품별 추정·동향 분석

• 부문 대시보드
• 세계의 항체 생산 시장 : 변동 분석 : 제품별
• 세계의 항체 생산 시장 규모와 동향 분석 : 제품별(2021-2033년)
• 기기
  • 바이오리액터
  • 크로마토그래피 시스템
  • 여과 시스템
• 소모품
  • 미디어
  • 완충액·시약
  • 크로마토그래피 수지·컬럼
  • 여과 소모품·부속품
  • 기타
• 소프트웨어

제5장 항체 생산 시장 : 프로세스별 추정·동향 분석

• 부문 대시보드
• 세계의 항체 생산 시장 : 변동 분석 : 프로세스별
• 세계의 항체 생산 시장 규모와 동향 분석 : 프로세스별(2021-2033년)
• 업스트림 처리
• 다운스트림 처리

제6장 항체 생산 시장 : 종류별 추정·동향 분석

• 부문 대시보드
• 세계의 항체 생산 시장 : 변동 분석 : 종류별
• 세계의 항체 생산 시장 규모와 동향 분석 : 종류별(2021-2033년)
• 단클론항체
• 다클론항체

제7장 항체 생산 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 세계의 항체 생산 시장 : 변동 분석 : 최종 용도별
• 세계의 항체 생산 시장 규모와 동향 분석 : 최종 용도별(2021-2033년)
• 제약·바이오테크놀러지 기업
• 검사실
• CRO·CDMO

제8장 항체 생산 시장 : 지역별 추정·동향 분석

• 항체 생산 시장 : 지역별 전망
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업 시장 상황 분석(2024년)
• 기업 개요/상장 기업
  • Lonza Group
  • Thermo Fisher Scientific, Inc.
  • AGC Biologics
  • Wuxi Biologics
  • Charles River Laboratories
  • Biointron
  • Danaher
  • Sartorius
  • Eppendorf
  • Merck KGaA

KSM

영문 목차

영문목차

Antibody Production Market Summary

The global antibody production market size was estimated at USD 15.44 billion in 2024 and is projected to reach USD 39.80 billion by 2033, growing at a CAGR of 11.2% from 2025 to 2033. Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, coupled with the growing demand for therapeutic antibodies, has led to the rapid growth of the antibody production market.

Personalized and Next-Generation Antibodies

The global antibody production market is experiencing a significant shift as the industry moves beyond conventional monoclonal antibodies toward more complex, next-generation formats. Personalized therapies are increasingly becoming the standard of care, with bispecific antibodies, antibody-drug conjugates (ADCs), and engineered monoclonal antibodies emerging as critical tools in targeting diseases with greater precision and efficacy. These novel modalities not only enhance therapeutic outcomes but also open new opportunities for biopharmaceutical companies to differentiate their portfolios in an increasingly competitive landscape.

The rise of next-generation antibodies is fueling demand for advanced and highly specialized production technologies. Unlike traditional mAbs, which rely on relatively standardized production processes, bispecifics and ADCs require more sophisticated cell line development, purification techniques, and conjugation platforms. Manufacturers are rapidly adopting innovative solutions such as high-density perfusion bioreactors, modular single-use systems, and integrated continuous bioprocessing to meet these evolving requirements. This technological advancement is essential to achieve cost-effective scalability while maintaining the high quality and safety standards expected for complex biologics.

Market growth is further reinforced by strong investment flows from both established pharmaceutical players and emerging biotech firms aiming to capitalize on next-generation antibody pipelines. Partnerships, acquisitions, and capacity expansion initiatives are accelerating globally, with a particular focus on regions that are investing heavily in biopharma infrastructure. As regulatory frameworks evolve to accommodate these innovative therapies, companies that can align their production capabilities with the unique demands of personalized and next-generation antibodies are well positioned to capture a larger share of this expanding market. Ultimately, the convergence of scientific innovation, manufacturing excellence, and strategic investment is reshaping the antibody production landscape and sustaining robust long-term growth.

Global Antibody Production Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global antibody production market based on product, process, type, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
  • Bioreactors
  • Multi-use Bioreactors
  • Single-use bioreactors
  • Chromatography systems
  • Filtration systems
• Consumables
  • Media
  • Buffers and reagents
  • Chromatography resins and columns
  • Filtration consumables and accessories
  • Others
  • Software
• Process Outlook (Revenue, USD Million, 2021 - 2033)
• Upstream Processing
• Downstream Processing
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Monoclonal Antibody
• Polyclonal Antibody
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and biotechnology companies
• Research laboratories
• CROs and CDMOs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Production Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
    • 3.2.1.1. Increased demand for therapeutic antibodies
    • 3.2.1.2. Increasing investment in R&D
    • 3.2.1.3. Rise in adoption of antibody production for personalized medicine and companion diagnostics
  • 3.2.2. Market Restraint Impact Analysis
    • 3.2.2.1. Stringent government regulations
• 3.3. Industry Analysis Tools
  • 3.3.1. PESTEL Analysis
  • 3.3.2. Porter's Five Forces Analysis

Chapter 4. Antibody Production Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Antibody Production Market Product Movement Analysis
• 4.3. Global Antibody Production Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Global Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Bioreactors
    • 4.4.2.1. Global Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
    • 4.4.2.2. Multi-use Bioreactor
      • 4.4.2.2.1. Global Multi-Use Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
    • 4.4.2.3. Single-use Bioreactor
      • 4.4.2.3.1. Global Single-Use Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.4.3. Chromatography Systems
    • 4.4.3.1. Global Chromatography Systems Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.4.4. Filtration Systems
    • 4.4.4.1. Global Filtration Systems Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
• 4.5. Consumables
  • 4.5.1. Global Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Media
    • 4.5.2.1. Global Media Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.3. Buffers and Reagents
    • 4.5.3.1. Global Buffers and Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.4. Chromatography Resins and Columns
    • 4.5.4.1. Global Chromatography Resins and Columns Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.5. Filtration Consumables and Accessories
    • 4.5.5.1. Global Filtration Consumables and Accessories Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.6. Others
    • 4.5.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
• 4.6. Software
  • 4.6.1. Global Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Antibody Production Market: Process Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Antibody Production Market Process Movement Analysis
• 5.3. Global Antibody Production Market Size & Trend Analysis, by Process, 2021 to 2033 (USD Million)
• 5.4. Upstream Processing
  • 5.4.1. Global Upstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Downstream Processing
  • 5.5.1. Global Downstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Antibody Production Market: Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Antibody Production Market Type Movement Analysis
• 6.3. Global Antibody Production Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 6.4. Monoclonal Antibody
  • 6.4.1. Global Monoclonal Antibody Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Polyclonal Antibody
  • 6.5.1. Global Polyclonal Antibody Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Antibody Production Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Antibody Production Market End Use Movement Analysis
• 7.3. Global Antibody Production Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Global Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Research Laboratories
  • 7.5.1. Global Research Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. CROs and CDMOs
  • 7.6.1. Global CROs and CDMOs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Antibody Production Market: Regional Estimates & Trend Analysis

• 8.1. Antibody Production Market: Region Outlook
• 8.2. North America
  • 8.2.1. North America Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Scenario
    • 8.2.2.4. U.S. Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Scenario
    • 8.2.3.4. Canada Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Scenario
    • 8.2.4.4. Mexico Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Scenario
    • 8.3.2.4. UK Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Scenario
    • 8.3.3.4. Germany Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Scenario
    • 8.3.4.4. France Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Scenario
    • 8.3.5.4. Italy Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Scenario
    • 8.3.6.4. Spain Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Scenario
    • 8.3.7.4. Denmark Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Scenario
    • 8.3.8.4. Sweden Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Scenario
    • 8.3.9.4. Norway Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. China
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Scenario
    • 8.4.2.4. China Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Scenario
    • 8.4.3.4. Japan Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Scenario
    • 8.4.4.4. India Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Scenario
    • 8.4.5.4. South Korea Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Scenario
    • 8.4.6.4. Australia Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Scenario
    • 8.4.7.4. Thailand Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Scenario
    • 8.5.2.4. Brazil Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Scenario
    • 8.5.3.4. Argentina Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Scenario
    • 8.6.2.4. South Africa Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Scenario
    • 8.6.3.4. Saudi Arabia Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Scenario
    • 8.6.4.4. UAE Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Scenario
    • 8.6.5.4. Kuwait Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Lonza Group
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. AGC Biologics
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Wuxi Biologics
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Charles River Laboratories
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Biointron
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Sartorius
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Eppendorf
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Merck KGaA
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives

관련자료